{'fraction_non_alphanumeric': 0.01293103448275862, 'fraction_numerical': 0.0034482758620689655, 'mean_word_length': 5.710982658959537, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hemostatic effect and postoperative benefits of intramyometrial carbetocin injection during myomectomy: a randomized controlled trial

Objective The aim of this study was to observe the effect of intramyometrial carbetocin injection in reducing intraoperative blood loss during myomectomy and to study the possible postoperative benefits. Study design This was a randomized controlled trial. Patients and methods Forty women with symptomatic uterine leiomyomata scheduled for myomectomy were recruited in the study. They were divided into two groups of 20 patients each. In the control group, hemostasis was performed with the uterine artery tourniquet technique. Meanwhile, in the study group, hemostasis was performed through an intramyometrial injection of carbetocin. Results Injection of intramyometrial carbetocin was associated with less blood loss during myomectomy. Moreover, it may lower the need for blood transfusion. Patients in whom carbetocin was used showed lower drop in their hemoglobin and hematocrit levels when measured 48 h postoperatively. Conclusion Carbetocin appears to be an effective drug in minimizing blood loss during myomectomy.